



IsoFlow™ Catheter Device



Dear Cancer Treatment Specialist:

The patient who has given you this letter is interested in exploring the use of the IsoFlow™ catheter as a possible treatment option for their wellness plan. This shows great promise as an effective targeted treatment regime that limits the majority of the negative consequences associated with traditional systemic chemotherapy protocols. IsoFlow™ can provide an additional treatment alternative for patients who are not surgical candidates, or for those patients where RF ablation, chemoembolization, radiation, and/or systemic chemotherapy is not a viable option.

The IsoFlow™ catheter has just received FDA approval as a Class II medical device, is available by prescription, and is already being used to treat patients throughout the United States. The IsoFlow™ procedure starts when the catheter is inserted into the artery where the tumor is located, and after the dual-balloon design feature of the catheter is inflated, the blood supply from that artery to the tumor is cut off without impeding the normal flow of blood through the artery. The catheter allows for the targeted delivery via sideways perfusion of the indicated chemotherapy medication, which is a unique capability that allows injection into areas where physicians were previously unable to treat directly using pressure. By utilizing this approach to fluid delivery, you can increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes, with the added benefit of allowing the patient to focus on fighting the cancer, and not the negative side effects of traditional chemotherapy.

While we cannot shrink every tumor, the IsoFlow™ procedure targets tumors that are life threatening, turning a potentially fatal disease into a manageable illness. The IsoFlow™ catheter shows great promise in cases involving challenging arterial anatomy. Furthermore, the IsoFlow™ catheter can treat any accessible tumor with a defined vasculature; including brain, liver, kidney, lung, and breast, among others.

The IsoFlow™ catheter is an outpatient procedure that takes about an hour. Among the doctors who are onboard with the IsoFlow process are two stand-out doctors at Stanford University School of Medicine who are embracing this new technology. Dr. Michael Dake, Former Chief of Interventional Radiology and current Professor of Cardiothoracic Surgery, and Dr. Huy Do, an Interventional Neuroradiological Surgeon, both believe that IsoFlow™'s targeted delivery system, which leaves adjacent normal healthy tissue unscathed, can reduce complications, improve results, and benefit patients, and is a valuable addition to the cancer treatment arsenal.

I encourage you to visit our website where you will find a considerable amount of data. I am available to discuss any questions or concerns you may have regarding the IsoFlow™ catheter. Thank you for taking the time to consider if the IsoFlow™ catheter would be a viable treatment option for your patient.

Mr. Robert Goldman, CEO

Vascular Designs

(408) 484-9010

rgoldman@vasculardesigns.com

<http://www.vasculardesigns.com/news.htm>